IgG Anti-IgE Autoantibodies in Immunoregulation

Stadler, Beda M.; Qiu, Gang; Vogel, Monique; Jarolim, E.; Miescher, Sylvia; Aebischer, Iwan; Weck, A.L. de

doi:10.1159/000235332

Cited by 23 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autoantibodies have been documented as either anaphylactogenic or not [9], We have also shown that the phenomenon of basophil releasability is probably related to a certain type o f anti-IgE (blocking or triggering) binding to cytophilic IgE [10], In addition. anti-IgE antibodies purified from complexes have been shown to both inhibit and in crease binding of IgE to the low-affinity receptor for IgE (FceRII also known asCD23).…”

Section: Introductionmentioning

confidence: 75%

Domain-Specific Anti-IgE Antibodies Interfere with IgE Binding to FcεRII

Miescher

Vogel²,

Stämpfli³

et al. 1994

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Human anti-IgE autoantibodies have been identified and implicated in the regulation of IgE-mediated reactions and IgE synthesis. In order to study the potential regulatory role of anti-IgE antibodies on IgE binding to the FcεRII we used a panel of IgE-specific monoclonal antibodies that were mapped by Western blotting against a series of recombinant ε domain peptides. Antibodies specific for all ε domains were detected except those against CεHl. Using a competitive inhibition cell-binding assay on FcεRII + 8866 cells, we identified two major patterns of anti-IgE activity. Antibodies specific for the CεH3 domain removed IgE whereas those specific for the CεH2 domain enhanced IgE binding to the FcεRII. The anti-CεH2 antibodies, in contrast to the anti-CεFD antibodies, could not dissociate cell-bound IgE from the FcεRII. Using preformed immune complexes of IgE and anti-IgE antibodies, it was clear that the anti-CεH2 antibodies bound more IgE to the FcεRII by addition of immune complexes to the cell surface. Our results suggest that the opposing actions of either inhibition or enhancement of IgE binding by anti-IgE antibodies are related to their ε domain specificity.

show abstract

Section: Introductionmentioning

confidence: 75%

Domain-Specific Anti-IgE Antibodies Interfere with IgE Binding to FcεRII

Miescher

Vogel²,

Stämpfli³

et al. 1994

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mast cells and basophils, in fact, are activated not only by IgE interaction with their receptor (direct anaphylaxis), but also by anti-IgE and anti-FcεRIα antibodies (''reverse type'' anaphylaxis) (11). It is clear that some of these autoantibodies could modulate the immune responses inhibiting IgE bound to their receptor, or, as occurs for some CIU cases, triggering the receptor to induce mediator release (13). It is clear that some of these autoantibodies could modulate the immune responses inhibiting IgE bound to their receptor, or, as occurs for some CIU cases, triggering the receptor to induce mediator release (13).…”

Section: Discussionmentioning

confidence: 99%

Cyclosporin a in Patients Affected by Chronic Idiopathic Urticaria: A Therapeutic Alternative

Loria

Dambra

D'Oronzio

et al. 2001

Immunopharmacology and Immunotoxicology

View full text Add to dashboard Cite

Chronic Idiopathic Urticaria (CIU) is a cutaneous disorder for which there is no identifiable specific etiologic agent. Some recent evidences suggest that CIU might be an autoimmune disease. We analyzed immunological features occurring in CIU and evaluated effectiveness and tolerance of Cyclosporin A (CsA) treatment in patients unresponsive to antihistaminic treatment. Twenty patients with CIU were recruited after a selective diagnostic protocol and were divided into two groups. CsA was prescribed for group 1 and Prednisone for group 2 as control, for 8 weeks. Before and after the therapy we performed on all patients immunological studies. For all patients symptoms disappeared after a few days of therapy. Before therapy all patients showed activated B cells (CD19+CD23+ cells) and among B CD19+ cells, about 20% were CD5+ (cells that synthesize natural autoantibodies). After treatment with Prednisone in group 2, a significant reduction of CD4+ lymphocytes (p = 0,01) was observed. Our findings might support the CIU autoimmune pathogenetic hypothesis. The clinical remission in the CsA-treated group confirmed the therapeutic effectiveness of this therapy in antihistaminic unresponsive CIU and, at dosage used, side effects were rare, mild and reversible. Thus, CsA might be a good therapeutic alternative in CIU patients unresponsive to conventional treatments.

show abstract

“…All other antibodies were anaphylactogenic although to different degrees. Our nonanaphylatogenic antibody (BSW17, [27]) also very ef fectively inhibited the binding of IgE of FceRI [28], How ever, further analysis clearly showed that this antibody nevertheless was capable of recognizing surface IgE but was obviously not capable of crosslinking IgE. Further more, in subsequent receptor dissociation studies we could show that this antibody was in addition capable of removing surface IgE [28], Thus, it represented a real 'de sensitizing' antibody.…”

Section: Anti-lge Antibody and Ige-binding To Fcerimentioning

confidence: 99%

Biological Activities of Anti-IgE Antibodies

Stadler

Stämpfli

Miescher

et al. 1993

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Naturally occurring anti-IgE autoantibodies represent a heterogeneous mixture of antibodies with diverse specificities and biological functions. By using murine monoclonal anti-IgE autoantibodies directed against different epitopes on the IgE molecule as a model for autoantibodies, we could show that only a minority of antibodies combine all beneficial biological activities, such as the activity of inhibiting in vitro IgE synthesis, removing IgE from the surface of CD23+ cells and not being anaphylactogenic. While it is difficult to isolate and measure anti-IgE antibodies in human serum, it is now possible to generate such human anti-IgE antibodies by the method of repertoire cloning. Thus, human recombinant antibodies against IgE may become available for the treatment of atopic disease.

show abstract

IgG Anti-IgE Autoantibodies in Immunoregulation

Cited by 23 publications

References 4 publications

Domain-Specific Anti-IgE Antibodies Interfere with IgE Binding to FcεRII

Domain-Specific Anti-IgE Antibodies Interfere with IgE Binding to FcεRII

Cyclosporin a in Patients Affected by Chronic Idiopathic Urticaria: A Therapeutic Alternative

Biological Activities of Anti-IgE Antibodies

Contact Info

Product

Resources

About